NASDAQ : PHAT
Phathom Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.22 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 494.06M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 438.45M |
| Enterprise Value | 809.35M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 79.43M |
| Shares Outstanding | 79.43M |
| Shares Change (YoY) | +12.33% |
| Shares Change (QoQ) | +1.37% |
| Owned by Insiders (%) | 3.62% |
| Owned by Institutions (%) | 70.24% |
| Float | 64.07M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 34.36 |
| PS Ratio | 1.66 |
| Forward PS | 1.04 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.76 |
| Quick Ratio | 1.67 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.41 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -5.44% |
| Return on Invested Capital (ROIC) | -8.64% |
| Return on Capital Employed (ROCE) | -14.96% |
| Weighted Average Cost of Capital (WACC) | 8.06% |
| Revenue Per Employee | $740,919 |
| Profits Per Employee | -$223,709 |
| Employee Count | 371 |
| Asset Turnover | 0.94 |
| Inventory Turnover | 9.45 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -57.58% |
| 50-Day Moving Average | 7.64 |
| 200-Day Moving Average | 10.44 |
| Relative Strength Index (RSI) | 33.51 |
| Average Volume (20 Days) | 1,710,138 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.78M |
| Short Previous Month | 10.11M |
| Short % of Shares Out | 12.32% |
| Short % of Float | 15.27% |
| Short Ratio (days to cover) | 6.89 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 274.88M |
| Gross Profit | 221.78M |
| Operating Income | -25.46M |
| Pretax Income | -83.00M |
| Net Income | -83.00M |
| EBITDA | -24.98M |
| EBIT | -25.46M |
| Loss Per Share | -$1.02 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 184.56M |
| Total Debt | 555.45M |
| Net Cash | -370.89M |
| Net Cash Per Share | -$4.67 |
| Equity (Book Value) | -347.64M |
| Book Value Per Share | -4.28 |
| Working Capital | 133.11M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -20.74M |
| Capital Expenditures | -302,000 |
| Depreciation & Amortization | 472,000 |
| Net Borrowing | -55.80M |
| Free Cash Flow | -21.04M |
| FCF Per Share | -$0.26 |
Margins
| Measure | Value |
|---|
| Gross Margin | 80.68% |
| Operating Margin | -9.26% |
| Pretax Margin | -30.19% |
| Profit Margin | -30.19% |
| EBITDA Margin | -9.09% |
| EBIT Margin | -9.26% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.33% |
| Shareholder Yield | -12.33% |
| Earnings Yield | -18.53% |
| FCF Yield | -4.61% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $20.05 |
| Price Target Difference | 263.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 55.54% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.47 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |